Martina Pagliuca, Marco Donato, Agostina Lagodin D'Amato, Mario Rosanova, Anna Orsola Maria Russo, Roberta Scafetta, Carmine De Angelis, Meghna V Trivedi, Fabrice André, Grazia Arpino, Lucia Del Mastro, Michelino De Laurentiis, Fabio Puglisi, Mario Giuliano
Estrogen receptor (ER) signaling represents the main driver of tumor growth and survival in hormone receptor positive (HR+) breast cancer (BC). Thus, endocrine therapy (ET) alone or in combination with targeted agents constitutes the mainstay of the treatment for this BC subtype. Despite its efficacy, intrinsic or acquired resistance to ET occurs in a large proportion of cases, mainly due to aberrant activation of ER signaling (i.e. through ligand-independent ER activation, in the presence of estrogen receptor 1 (ESR1) gene aberration or ER protein phosphorylation) and/or the upregulation of escape pathways, such as the PI3K/AKT/mTOR pathway...
December 2022: Critical Reviews in Oncology/hematology
Emily A Kolyvas, Carlos Caldas, Kathleen Kelly, Saif S Ahmad
Despite significant progress in breast cancer (BC) therapy, it is globally the most commonly diagnosed cancer and leads to the death of over 650,000 women annually. Androgen receptor (AR) is emerging as a potential new therapeutic target in BC. While the role of AR is well established in prostate cancer (PCa), its function in BC remains incompletely understood. Emerging data show that AR's role in BC is dependent on several factors including, but not limited to, disease subtype, tumour microenvironment, and levels of circulating oestrogens and androgens...
November 14, 2022: Breast Cancer Research: BCR
Eoin P Kerin, Matthew G Davey, Ray P McLaughlin, Karl J Sweeney, Michael K Barry, Carmel M Malone, Sami Abd Elwahab, Aoife J Lowery, Michael J Kerin
INTRODUCTION: Traditionally, Nottingham prognostic index (NPI) informed prognosis in patients with estrogen receptor positive, human epidermal growth factor receptor-2 negative, node negative (ER+/HER2-/LN-) breast cancer. At present, OncotypeDX© Recurrence Score (RS) predicts prognosis and response to adjuvant chemotherapy (AC). AIMS: To compare NPI and RS for estimating prognosis in ER + breast cancer. METHODS: Consecutive patients with ER+/HER2-/LN- disease were included...
November 3, 2022: Breast: Official Journal of the European Society of Mastology
C Sessa, J Balmaña, S L Bober, M J Cardoso, N Colombo, G Curigliano, S M Domchek, D G Evans, D Fischerova, N Harbeck, C Kuhl, B Lemley, E Levy-Lahad, M Lambertini, J A Ledermann, S Loibl, K-A Phillips, Paluch Shimon
No abstract text is available yet for this article.
October 19, 2022: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Azra Ajkunic, Faruk Skenderi, Nada Shaker, Saghir Akhtar, Janez Lamovec, Zoran Gatalica, Semir Vranic
Acinic cell carcinoma of the breast is a rare special subtype of breast cancer in the category of salivary gland-type tumors. It is morphologically similar to acinic cell carcinomas of salivary glands and pancreas and has a triple-negative phenotype (estrogen receptor-negative, progesterone receptor-negative, and Her-2/neu negative). Its molecular genomic features are more similar to triple-negative breast cancer of no special type than to its salivary gland counterpart. However, the clinical course of the mammary acinic cell carcinoma appears to be less aggressive than the usual triple-negative breast carcinomas...
October 28, 2022: Breast: Official Journal of the European Society of Mastology
Cheng-Wei Lin, Meng-Hsuan Chiang, Ka-Wai Tam
BACKGROUND: Because the lesions of mammary Paget disease (MPD) are often limited to the nipple-areolar complex, the extension of optimal tumor excision is inconclusive. Moreover, the risk of potential tumor upstaging is unknown; therefore, the application of sentinel lymph node biopsy (SLNB) is required for analysis. We systematically reviewed the real-world data to evaluate the optimal treatment and potential predictors of poorer prognosis for MPD. METHODS: The PubMed, Embase, and Cochrane Library databases were searched for relevant studies...
October 26, 2022: International Journal of Surgery
Elisa Agostinetto, Joseph Gligorov, Martine Piccart
The treatment of breast cancer has improved dramatically over the past century, from a strictly surgical approach to a coordinated one, including local and systemic therapies. Systemic therapies for early-stage disease were initially tested against observation or placebo only in adjuvant trials. Subsequent clinical trials focusing on treatment 'fine-tuning' had a marked increase in cohort size, duration and costs, leading to a growing interest in the neoadjuvant setting in the past decade. Neoadjuvant trial designs have the advantages of enabling the direct evaluation of treatment effects on tumour diameter and offer unique translational research opportunities through the comparative analysis of tumour biology before, during and after treatment...
October 17, 2022: Nature Reviews. Clinical Oncology
Matthew G Davey, Michael J Kerin
Introduction: Randomised clinical trials (RCTs) report similar outcomes following neoadjuvant (NAC) and adjuvant chemotherapy (AC) in breast cancer. "Fragility Indices" (FI) test significance reversal reported in RCTs. Aim: To evaluate the FI of findings from RCTs assessing outcomes of NAC and AC. Methods: A systematic review was performed as per PRISMA guidelines. RCTs of interest were identified and data pooled. Fisher's exact test was used to calculate FI for reversal of statistical significance for dichotomous outcomes...
2022: Breast Cancer: Targets and Therapy
Julie O Culver
No abstract text is available yet for this article.
October 14, 2022: Annals of Surgical Oncology
Mattea Reinisch, Michael Untch, Rolf Mahlberg, Toralf Reimer, Thomas Hitschold, Frederik Marmé, Mustafa Aydogdu, Sabine Schmatloch, Hans-Joachim Lück, Marcus Schmidt, Ekkehart Ladda, Bruno Valentin Sinn, Peter Klare, Wolfgang Janni, Christian Jackisch, Carsten Denkert, Sabine Seiler, Thomas Göhler, Laura Michel, Nicole Burchardi, Elmar Stickeler, Julia Rey, Nicole Klutinus, Volker Möbus, Sibylle Loibl
BACKGROUND: Trastuzumab given intravenously in combination with chemotherapy is standard of care for patients with early HER2-positive breast cancer (BC). Different randomised studies have shown equivalent efficacy of a subcutaneous injection into the thigh compared to the intravenous formulation. Other body regions for injection have not been investigated but might be more convenient for patients. METHODS: After surgery, patients were randomised to receive either subcutaneous trastuzumab into the thigh or into the abdominal wall (AW)...
October 5, 2022: Breast: Official Journal of the European Society of Mastology
Francesco Schettini, Sergio Venturini, Mario Giuliano, Matteo Lambertini, David J Pinato, Concetta Elisa Onesti, Pietro De Placido, Nadia Harbeck, Diana Lüftner, Hannelore Denys, Peter Van Dam, Grazia Arpino, Khalil Zaman, Giorgio Mustacchi, Joseph Gligorov, Ahmad Awada, Mario Campone, Hans Wildiers, Alessandra Gennari, Vivianne Tjan-Heijnen, Rupert Bartsch, Javier Cortes, Ida Paris, Miguel Martín, Sabino De Placido, Lucia Del Mastro, Guy Jerusalem, Giuseppe Curigliano, Aleix Prat, Daniele Generali
Metastatic triple-negative breast cancer (mTNBC) is a poor prognostic disease with limited treatments and uncertain therapeutic algorithms. We performed a systematic review and multiple Bayesian network meta-analyses according to treatment line to establish an optimal therapeutic sequencing strategy for this lethal disease. We included 125 first-line trials (37,812 patients) and 33 s/further-lines trials (11,321 patients). The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall response rates (ORR), overall survival (OS) and safety, for first and further lines, separately...
September 28, 2022: Cancer Treatment Reviews
Oluwadamilola M Fayanju, Christine E Edmonds, Sylvia A Reyes, Cletus Arciero, Vivian J Bea, Angelena Crown, Kathie-Ann Joseph
Randomized, clinical trials have established the efficacy of screening mammography in improving survival from breast cancer for women through detection of early, asymptomatic disease. However, disparities in survival rates between black women and women from other racial and ethnic groups following breast cancer diagnosis persist. Various professional groups have different, somewhat conflicting, guidelines with regards to recommended age for commencing screening as well as recommended frequency of screening exams, but the trials upon which these recommendations are based were not specifically designed to examine benefit among black women...
October 3, 2022: Annals of Surgical Oncology
Theresa Schwartz, Ashley D Marumoto, Armando E Giuliano
No abstract text is available yet for this article.
October 4, 2022: Annals of Surgical Oncology
Nadeem Bilani, Fionnuala Crowley, Mohamed Mohanna, Mira Itani, Marita Yaghi, Diana Saravia, Iktej Jabbal, Barbara Dominguez, Hong Liang, Zeina Nahleh
The 21-gene recurrence score assay has been validated as a predictive biomarker in early-stage HR+ and HER2-breast cancer. It is not indicated for use in HER2+ disease based on national guidelines. In this study, we assessed the value of 21-gene recurrence score (RS), or OncotypeDX (ODX), testing in HR+/HER2+ breast cancer. We used the National Cancer Database to identify patients with stages I-II, HR+/HER2+ breast cancer who received multi-gene testing with ODX. We then explored the prognostic and predictive value of this biomarker through various forms of survival modeling...
September 6, 2022: Breast: Official Journal of the European Society of Mastology
Melina Arnold, Eileen Morgan, Harriet Rumgay, Allini Mafra, Deependra Singh, Mathieu Laversanne, Jerome Vignat, Julie R Gralow, Fatima Cardoso, Sabine Siesling, Isabelle Soerjomataram
BACKGROUND: Breast cancer is the most commonly diagnosed cancer worldwide, and its burden has been rising over the past decades. In this article, we examine and describe the global burden of breast cancer in 2020 and predictions for the year 2040. METHODS: Estimates of new female breast cancer cases and deaths in 2020 were abstracted from the GLOBOCAN database. Age-standardized incidence and mortality rates were calculated per 100,000 females by country, world region, and level of human development...
September 2, 2022: Breast: Official Journal of the European Society of Mastology
David A Mankoff, Amy S Clark, Christine E Edmonds, Sophia R O'Brien, Austin R Pantel
No abstract text is available yet for this article.
August 30, 2022: Journal of Clinical Oncology
Diogo Silva, Alexandra Mesquita
Representing 15% to 20% of all invasive breast cancers, adjuvant systemic treatment for early-stage, high-risk triple-negative breast cancer (TNBC) is preferentially done in the neoadjuvant setting based on a chemotherapy backbone of anthracyclines and taxanes. Pathological complete response to neoadjuvant treatment constitutes the main objective, regarding its correlation with oncological outcomes. The optimal neoadjuvant regimen to achieve the highest rates of pathological complete response is still under investigation, with the increasing knowledge on the molecular pathways, genomic sequencing, and immunological profile of TNBC allowing for the development of a wide array of new therapeutic options...
2022: Breast Cancer: Basic and Clinical Research
Henry M Kuerer
No abstract text is available yet for this article.
August 24, 2022: Annals of Surgical Oncology
Eugénie Guimier, Louise Carson, Benny David, James M Lambert, Enda Heery, R Karl Malcolm
Capsular contracture is a common complication associated with breast implants following reconstructive or aesthetic surgery in which a tight or constricting scar tissue capsule forms around the implant, often distorting the breast shape and resulting in chronic pain. Capsulectomy (involving full removal of the capsule surrounding the implant) and capsulotomy (where the capsule is released and/or partly removed to create more space for the implant) are the most common surgical procedures used to treat capsular contracture...
December 2022: Journal of Surgical Research
Shahla Bari, David Boulware, Jiannong Li, Loretta Loftus, Aixa Soyano Muller, Zena Jameel, Hung Khong, Brian J Czerniecki, Ricardo L B Costa
Purpose: Estrogen receptor-positive (ER+ ) breast cancer (BC) is a heterogeneous disease, and there is an ongoing debate regarding the optimal cut point for clinically relevant ER expression. We used a real-world database to assess the prognostic and predictive values of lower ER expression levels on treatment outcomes with endocrine therapy. Methods: We used a nationwide electronic health record database. Descriptive statistics were used to evaluate the association between ER expression, tumor characteristics, and treatment patterns among patients with early-stage BC...
2022: Breast Cancer: Targets and Therapy
2022-08-19 16:04:14
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.